摘要
目的探讨复方甘草酸苷联合还原型谷胱甘肽治疗酒精性肝硬化患者的临床疗效。方法选择2016年8月~2017年8月商丘市长征人民医院内科收治的酒精性肝硬化患者50例,使用随机数表法将所有患者分为两组,观察组与对照组各25例。给予对照组患者还原型谷胱甘肽治疗,观察组采用复方甘草酸苷联合还原型谷胱甘肽治疗方式,比较两组患者肝功能、肝纤维化指标水平改善情况。结果治疗后观察组患者AST、ALT、GGT与TBIL水平分别为(92.48±33.60)U/L、(67.24±25.86)U/L、(154.23±67.09)U/L、(29.37±10.05)μmol/L,均低于对照组的(234.71±49.56)U/L、(189.72±41.53)U/L、(276.39±108.06)U/L、(54.19±18.26)μmol/L,差异有统计学意义(P<0.05);治疗后观察组PCⅢ、IV-C及HA指标水平分别为(102.73±29.84)μg/L、(62.58±14.39)μg/L、(77.39±20.01)μg/L,均低于对照组的(150.21±43.06)μg/L、(104.57±33.06)μg/L、(169.83±52.14)μg/L,差异有统计学意义(P<0.05)。结论酒精肝硬化患者采用复方甘草酸苷与还原型谷胱甘肽联合治疗方式,能够有效改善其肝功能及肝纤维指标水平,有利于帮助患者缓解各项临床症状,疗效确切且安全可靠,具有较高的临床应用价值。
Objective To investigate the clinical efficacy of compound glycyrrhizin combined with reduced glutathione on liver function indexes in patients with alcoholic cirrhosis. Methods 50 patients with alcoholic cirrhosis in the department of internal medicine of Shangqiu Changzheng people's hospital from August 2016 to August 2017 were selected, and they were divided into observation group and control group by random number table, with 25 cases in each group. Control group was given reduced glutathione, while observation group was treated with compound glycyrrhizin combined with reduced glutathione. The liver function and indexes of hepatic fibrosis were compared between the two groups. Results After treatment, the levels of AST, ALT, GGT, TBIL in observation group [(92.48±33.60)U/L,(67.24±25.86)U/L,(154.23±67.09)U/L,(29.37±10.05)μmol/L] were lower than control group [(234.71±49.56)U/L,(189.72±41.53)U/L,(276.39±108.06)U/L,(54.19±18.26)μmol/L](P〈0.05); After treatment, the levels of PC Ⅲ, IV-C, HA in observation group [(102.73±29.84)μg/L,(62.58±14.39)μg/L,(77.39±20.01)μg/L] were lower than control group [(150.21±43.06)μg/L,(104.57±33.06)μg/L,(169.83±52.14)μg/L](P〈0.05). Conclusion Compound glycyrrhizin combined with reduced glutathione in treatment of alcoholic cirrhosis is safe and reliable, it can effectively improve liver function and hepatic fibrosis indexes, relieve clinical symptoms, which has higher clinical application value.
作者
侯保全
HOU Bao-quan(Department of Internal Medicine,Shangqiu Changzheng People’s Hospital,Shangqiu,Henan,476000,China)
出处
《临床研究》
2018年第9期32-33,共2页
Clinical Research